{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:30:23Z","timestamp":1786120223966,"version":"build-2736575974"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1S","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:p>The introduction of TNF blockers in the therapeutic armamentarium of inflammatory bowel diseases (IBD) has largely advanced the way by which clinicians manage these disorders. However, some patients develop de novo immune-mediated diseases during the treatment. We here present the case of paradoxical hidradenitis suppurativa, a chronic inflammatory skin disease characterized by the development of recurrent nodules and abscesses in intertriginous areas, in a 20-year-old, nonsmoker, normal-weight women, with no family history of hidradenitis suppurativa or IBD, diagnosed with nonstricturing nonpenetrating ileocolonic Crohn\u2019s disease in 2013, during treatment with infliximab. Infliximab discontinuation was followed by a significant improvement of skin lesions. We also discuss 22 additional cases of paradoxical hidradenitis suppurativa in IBD patients on TNF antagonists reported in the literature with the aim to identify potential risk factors for the development of such a complication. All the patients had Crohn\u2019s disease, and the majority of them were women (19\/23; 82.6%). All cases occurred during therapy with anti-TNF agents [14\/23 (61%) patients were treated with adalimumab and 9\/23 (39%) patients were treated with infliximab]. The therapeutic approach directed at maintaining\/holding the undergoing biologic therapy is still uncertain. Further studies are needed to determine the most appropriate treatment choice toward ongoing biologic therapy.<\/jats:p>","DOI":"10.1097\/meg.0000000000002170","type":"journal-article","created":{"date-parts":[[2021,4,22]],"date-time":"2021-04-22T02:04:03Z","timestamp":1619057043000},"page":"e1046-e1050","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":8,"title":["Paradoxical hidradenitis suppurativa in Crohn\u2019s disease patients receiving infliximab: a case report and review of literature"],"prefix":"10.1097","volume":"33","author":[{"given":"Silvia","family":"Salvatori","sequence":"first","affiliation":[{"name":"Gastroenterology Unit, Department of Systems Medicine, University of Rome \u201cTor Vergata\u201d, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Marafini","sequence":"additional","affiliation":[{"name":"Gastroenterology Unit, Department of Systems Medicine, University of Rome \u201cTor Vergata\u201d, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Monteleone","sequence":"additional","affiliation":[{"name":"Gastroenterology Unit, Department of Systems Medicine, University of Rome \u201cTor Vergata\u201d, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,4,19]]},"reference":[{"key":"R1-20240821","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.clim.2018.03.004","article-title":"Biological therapies in inflammatory bowel disease: Beyond anti-TNF therapies.","volume":"206","author":"Katsanos","year":"2019","journal-title":"Clin Immunol"},{"key":"R2-20240821","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1111\/j.1365-2036.2011.04599.x","article-title":"Review article: remission rates achievable by current therapies for inflammatory bowel disease.","volume":"33","author":"Peyrin-Biroulet","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"R3-20240821","doi-asserted-by":"crossref","first-page":"e000239","DOI":"10.1136\/rmdopen-2015-000239","article-title":"Paradoxical reactions under TNF-\u03b1 blocking agents and other biological agents given for chronic immune-mediated diseases: an analytical and comprehensive overview.","volume":"2","author":"Toussirot","year":"2016","journal-title":"RMD Open"},{"key":"R4-20240821","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1136\/gut.2005.082909","article-title":"The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications.","volume":"55","author":"Satsangi","year":"2006","journal-title":"Gut"},{"key":"R5-20240821","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1111\/j.1468-3083.2009.03356.x","article-title":"Hidradenitis suppurativa.","volume":"23","author":"Revuz","year":"2009","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R6-20240821","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1159\/000453355","article-title":"Quality of life and psychosocial implications in patients with hidradenitis suppurativa.","volume":"232","author":"Kouris","year":"2016","journal-title":"Dermatology"},{"key":"R7-20240821","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1016\/j.jid.2018.04.001","article-title":"Prevalence estimates for hidradenitis suppurativa among children and adolescents in the United States: a gender- and age-adjusted population analysis.","volume":"138","author":"Garg","year":"2018","journal-title":"J Invest Dermatol"},{"key":"R8-20240821","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1111\/j.1600-0625.2012.01552.x","article-title":"Hidradenitis suppurativa: viewpoint on clinical phenotyping, pathogenesis and novel treatments.","volume":"21","author":"van der Zee","year":"2012","journal-title":"Exp Dermatol"},{"key":"R9-20240821","first-page":"586","article-title":"Hidradenitis suppurativa for the nondermatology clinician.","volume":"33","author":"Patel","year":"2020","journal-title":"Proc (Bayl Univ Med Cent)"},{"key":"R11-20240821","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1111\/bjd.16101","article-title":"Population-based Clinical Practice Research Datalink study using algorithm modelling to identify the true burden of hidradenitis suppurativa.","volume":"178","author":"Ingram","year":"2018","journal-title":"Br J Dermatol"},{"key":"R12-20240821","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jaad.2016.08.031","article-title":"Inflammatory bowel disease is associated with hidradenitis suppurativa: results from a multicenter cross-sectional study.","volume":"76","author":"Deckers","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"R13-20240821","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1365-2133.2009.09430.x","article-title":"Hidradenitis suppurativa and inflammatory bowel disease: are they associated? Results of a pilot study.","volume":"162","author":"van der Zee","year":"2010","journal-title":"Br J Dermatol"},{"key":"R14-20240821","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1016\/j.jid.2016.04.003","article-title":"Hidradenitis suppurativa and inflammatory bowel disease: a cross-sectional study of 3,207 patients.","volume":"136","author":"Shalom","year":"2016","journal-title":"J Invest Dermatol"},{"key":"R15-20240821","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.cgh.2015.04.173","article-title":"Hidradenitis suppurativa in patients with inflammatory bowel disease: a population-based cohort study in Olmsted county, Minnesota.","volume":"14","author":"Yadav","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R16-20240821","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1001\/jamadermatol.2019.0891","article-title":"Association of hidradenitis suppurativa with inflammatory bowel disease: a systematic review and meta-analysis.","volume":"155","author":"Chen","year":"2019","journal-title":"JAMA Dermatol"},{"key":"R17-20240821","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1007\/s10620-018-4919-5","article-title":"Risk factors for hidradenitis suppurativa in patients with inflammatory bowel disease.","volume":"63","author":"Lukach","year":"2018","journal-title":"Dig Dis Sci"},{"key":"R18-20240821","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3109\/09546634.2015.1094179","article-title":"Observational case series on adalimumab-induced paradoxical hidradenitis suppurativa.","volume":"27","author":"Delobeau","year":"2016","journal-title":"J Dermatolog Treat"},{"key":"R19-20240821","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/j.jaad.2016.01.018","article-title":"Hidradenitis suppurativa (HS): an unrecognized paradoxical effect of biologic agents (BA) used in chronic inflammatory diseases.","volume":"74","author":"Faivre","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"R20-20240821","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1159\/000444442","article-title":"Two cases of paradoxical hidradenitis suppurativa while on adalimumab.","volume":"10","author":"Harvin","year":"2016","journal-title":"Case Rep Gastroenterol"},{"key":"R21-20240821","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1159\/000506074","article-title":"Paradoxical hidradenitis suppurativa in patients receiving TNF-\u03b1 inhibitors: case series, systematic review, and case meta-analysis.","volume":"236","author":"Salvador-Rodriguez","year":"2020","journal-title":"Dermatology"},{"key":"R22-20240821","doi-asserted-by":"crossref","first-page":"293","DOI":"10.2147\/CEG.S263685","article-title":"Hidradenitis suppurativa as a paradoxical side effect to the use of adalimumab in patients with Crohn\u2019s disease?","volume":"13","author":"Beraldo","year":"2020","journal-title":"Clin Exp Gastroenterol"},{"key":"R23-20240821","first-page":"21","article-title":"Hidradenitis suppurativa in Crohn\u2019s disease during adalimumab therapy: a paradox?","volume":"26","author":"Martina","year":"2017","journal-title":"Acta Dermatovenerol Alp Pannonica Adriat"},{"key":"R24-20240821","doi-asserted-by":"crossref","first-page":"e226","DOI":"10.1111\/ijd.14585","article-title":"Paradoxical hidradenitis suppurativa to biologic agents: a case series and literature review.","volume":"58","author":"Neves","year":"2019","journal-title":"Int J Dermatol"},{"key":"R25-20240821","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1097\/MPG.0b013e3182474d78","article-title":"First episode of axillary acne inversa in a teenager on infliximab therapy for Crohn disease.","volume":"56","author":"Sava\u015fan","year":"2013","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"R26-20240821","doi-asserted-by":"crossref","first-page":"e12742","DOI":"10.1111\/dth.12742","article-title":"Development of hidradenitis suppurativa in a patient treated with ustekinumab for her psoriasis: a potential paradoxical reaction?","volume":"31","author":"Gkini","year":"2018","journal-title":"Dermatol Ther"},{"key":"R27-20240821","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.3389\/fimmu.2018.02965","article-title":"Hidradenitis suppurativa: a systematic review integrating inflammatory pathways into a cohesive pathogenic model.","volume":"9","author":"Vossen","year":"2018","journal-title":"Front Immunol"},{"key":"R28-20240821","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1111\/j.1365-2133.2011.10254.x","article-title":"Elevated levels of tumour necrosis factor (TNF)-\u03b1, interleukin (IL)-1\u03b2 and IL-10 in hidradenitis suppurativa skin: a rationale for targeting TNF-\u03b1 and IL-1\u03b2.","volume":"164","author":"van der Zee","year":"2011","journal-title":"Br J Dermatol"},{"key":"R29-20240821","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.jaad.2019.08.090","article-title":"Hidradenitis suppurativa: epidemiology, clinical presentation, and pathogenesis.","volume":"82","author":"Goldburg","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"R30-20240821","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1016\/j.jid.2016.04.021","article-title":"High copy numbers of \u03b2-defensin cluster on 8p23.1, confer genetic susceptibility, and modulate the physical course of hidradenitis suppurativa\/acne inversa.","volume":"136","author":"Giamarellos-Bourboulis","year":"2016","journal-title":"J Invest Dermatol"},{"key":"R31-20240821","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1007\/s10753-016-0492-2","article-title":"Expression of miRNA-155, miRNA-223, miRNA-31, miRNA-21, miRNA-125b, and miRNA-146a in the inflammatory pathway of hidradenitis suppurativa.","volume":"40","author":"Hessam","year":"2017","journal-title":"Inflammation"},{"key":"R32-20240821","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.jdermsci.2016.02.009","article-title":"Inflammation induced changes in the expression levels of components of the microRNA maturation machinery Drosha, Dicer, Drosha co-factor DGRC8 and Exportin-5 in inflammatory lesions of hidradenitis suppurativa patients.","volume":"82","author":"Hessam","year":"2016","journal-title":"J Dermatol Sci"}],"container-title":["European Journal of Gastroenterology &amp; Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MEG.0000000000002170","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T20:16:42Z","timestamp":1786047402000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MEG.0000000000002170"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,19]]},"references-count":31,"journal-issue":{"issue":"1S","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/meg.0000000000002170","relation":{},"ISSN":["0954-691X"],"issn-type":[{"value":"0954-691X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4,19]]}}}